ArticleFrontiers in oncology2022
MRI-Based Radiomics Features to Predict Treatment Response to Neoadjuvant Chemotherapy in Locally Advanced Rectal Cancer: A Single Center, Prospective Study.
Article in Frontiers in oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 2 syntheses or guidelines pooled it, 21 citations in OpenAlex.
- Radiomics Models as Tools for Predicting Genetic Mutations in Colorectal Cancer: A Systematic Review and Meta-Analysis.Journal of gastrointestinal cancer · 2026Pooled it
- Radiomic Analysis of MRI for Assessing Response to Neoadjuvant Chemoradiotherapy in Rectal Adenocarcinoma: A Systematic Review and Metaanalysis.Molecular imagingPooled it
- MRI-based multiregional radiomics for pretreatment prediction of pathologic complete response to neoadjuvant chemoradiation therapy in locally advanced rectal cancer: a bicenter study.Abdominal radiology (New York) · 2026Article
- Multiparametric MRI-derived biomarkers for preoperative prediction of recurrence and/or metastasis after neoadjuvant chemoradiotherapy in locally advanced rectal cancer.Quantitative imaging in medicine and surgery · 2026Article
- Radiomics-based artificial intelligence (AI) models in colorectal cancer (CRC) diagnosis, metastasis detection, prognosis, and treatment response prediction.Abdominal radiology (New York) · 2026Review
- Generative adversarial networks: multiparametric, multiregion super-resolution MRI in predicting lymph node metastasis in rectal cancer.Insights into imaging · 2026Article
- Research Progress of MRI-based Radiomics in Rectal CancerCurrent medical imaging · 2026Review
- Interpretable Dynamic MRI-ITH Model for Predicting Neoadjuvant Chemotherapy Response in Breast Cancer: A Multicenter Study.Journal of multidisciplinary healthcare · 2026Article
- Research progress in multimodal radiomics of rectal cancer tumors and peritumoral regions in MRI.Abdominal radiology (New York) · 2025Review
- Beyond the tumor region: Peritumoral radiomics enhances prognostic accuracy in locally advanced rectal cancer.World journal of gastroenterology · 2025Article
- Article
- Article
- Radiomics in colorectal cancer patients.World journal of gastroenterology · 2023Review
- Artificial intelligence-driven radiomics study in cancer: the role of feature engineering and modeling.Military Medical Research · 2023Review
- Review
- Article
- Role of radiomics in the diagnosis and treatment of gastrointestinal cancer.World journal of gastroenterology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This is a prospective, single center study aimed to evaluate the predictive power of peritumor and intratumor radiomics features assessed using T2 weight image (T2WI) of baseline magnetic resonance imaging (MRI) in evaluating pathological good response to NAC in patients with LARC (including Tany N+ or T3/4a Nany but not T4b). In total, 137 patients with LARC received NAC between April 2014 and August 2020. All patients were undergoing contrast-enhanced MRI and 129 patients contained small field of view (sFOV) sequence which were performed prior to treatment. The tumor regression grade standard was based on pathological response. The training and validation sets (n=91 vs. n=46) were established by random allocation of the patients. Receiver operating characteristic curve (ROC) analysis was applied to estimate the performance of different models based on clinical characteristics and radiomics features obtained from MRI, including peritumor and intratumor features, in predicting treatment response; these effects were calculated using the area under the curve (AUC). The performance and agreement of the nomogram were estimated using calibration plots. In total, 24 patients (17.52%) achieved a complete or near-complete response. For the individual radiomics model in the validation set, the performance of peritumor radiomics model in predicting treatment response yield an AUC of 0.838, while that of intratumor radiomics model is 0.805, which show no statically significant difference between then(P>0.05). The traditional and selective clinical features model shows a poor predictive ability in treatment response (AUC=0.596 and 0.521) in validation set. The AUC of combined radiomics model was improved compared to that of the individual radiomics models in the validation sets (AUC=0.844). The combined clinic-radiomics model yield the highest AUC (0.871) in the validation set, although it did not improve the performance of the radiomics model for predicting treatment response statically (P>0.05). Good agreement and discrimination were observed in the nomogram predictions. Both peritumor and intratumor radiomics features performed similarly in predicting a good response to NAC in patients with LARC. The clinic-radiomics model showed the best performance in predicting treatment response.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.